Heterologous vaccination with inactivated vaccine and mRNA vaccine augments antibodies against both spike and nucleocapsid proteins of SARS-CoV-2: a local study in Macao

被引:4
作者
Ng, Hoi Man [1 ]
Lei, Chon Lok [2 ]
Fu, Siyi [2 ]
Li, Enqin [2 ]
Leong, Sek In [1 ]
Nip, Chu Iong [1 ]
Choi, Nga Man [1 ]
Lai, Kai Seng [1 ]
Tang, Xi Jun [3 ]
Lei, Chon Leng [1 ]
Xu, Ren-He [2 ]
机构
[1] Kiang Wu Hosp, Lab Dept, Macau, Peoples R China
[2] Univ Macau, Fac Hlth Sci, Macau, Peoples R China
[3] Zhuhai Hosp Combined Tradit Chinese & Western Med, Lab Dept, Zhuhai, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
SARS-CoV-2; inactivated vaccine; mRNA vaccine; heterologous vaccinations; antibodies; spike proteins; nucleocapsid proteins; Macao;
D O I
10.3389/fimmu.2023.1131985
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The mRNA vaccines (RVs) can reduce the severity and mortality of severe acute respiratory syndrome coronavirus (SARS-CoV-2). However, almost only the inactivated vaccines (IVs) but no RVs had been used in mainland China until most recently, and the relaxing of its anti-pandemic strategies in December 2022 increased concerns about new outbreaks. In comparison, many of the citizens in Macao Special Administrative Region of China received three doses of IV (3IV) or RV (3RV), or 2 doses of IV plus one booster of RV (2IV+1RV). By the end of 2022, we recruited 147 participants with various vaccinations in Macao and detected antibodies (Abs) against the spike (S) protein and nucleocapsid (N) protein of the virus as well as neutralizing antibodies (NAb) in their serum. We observed that the level of anti-S Ab or NAb was similarly high with both 3RV and 2IV+1RV but lower with 3IV. In contrast, the level of anti-N Ab was the highest with 3IV like that in convalescents, intermediate with 2IV+1RV, and the lowest with 3RV. Whereas no significant differences in the basal levels of cytokines related to T-cell activation were observed among the various vaccination groups before and after the boosters. No vaccinees reported severe adverse events. Since Macao took one of the most stringent non-pharmaceutical interventions in the world, this study possesses much higher confidence in the vaccination results than many other studies from highly infected regions. Our findings suggest that the heterologous vaccination 2IV+1RV outperforms the homologous vaccinations 3IV and 3RV as it induces not only anti-S Ab (to the level as with 3RV) but also anti-N antibodies (via the IV). It combines the advantages of both RV (to block the viral entry) and IV (to also intervene the subsequent pathological processes such as intracellular viral replication and interference with the signal transduction and hence the biological functions of host cells).
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Glycosite-deleted mRNA of SARS-CoV-2 spike protein as a broad-spectrum vaccine
    Wu, Chung-Yi
    Cheng, Cheng-Wei
    Kung, Chih-Chuan
    Liao, Kuo-Shiang
    Jan, Jia-Tsrong
    Ma, Che
    Wong, Chi-Huey
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 119 (09)
  • [22] Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
    Wang, Hui
    Zhang, Yuntao
    Huang, Baoying
    Deng, Wei
    Quan, Yaru
    Wang, Wenling
    Xu, Wenbo
    Zhao, Yuxiu
    Li, Na
    Zhang, Jin
    Liang, Hongyang
    Bao, Linlin
    Xu, Yanfeng
    Ding, Ling
    Zhou, Weimin
    Gao, Hong
    Liu, Jiangning
    Niu, Peihua
    Zhao, Li
    Zhen, Wei
    Fu, Hui
    Yu, Shouzhi
    Zhang, Zhengli
    Xu, Guangxue
    Li, Changgui
    Lou, Zhiyong
    Xu, Miao
    Qin, Chuan
    Wu, Guizhen
    Gao, George Fu
    Tan, Wenjie
    Yang, Xiaoming
    CELL, 2020, 182 (03) : 713 - +
  • [23] Engineering mRNA vaccine with broad-spectrum protection against SARS-cov-2 variants
    Du, Shuang
    Yang, Liu
    Chen, Xingguang
    Chen, Yonghao
    Weng, Liang
    Huang, Hui
    Pang, Silin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 746
  • [24] Circular mRNA Vaccine against SARS-COV-2 Variants Enabled by Degradable Lipid Nanoparticles
    Huang, Ke
    Li, Na
    Li, Yingwen
    Zhu, Jiafeng
    Fan, Qianyi
    Yang, Jiali
    Gao, Yinjia
    Liu, Yuping
    Gao, Shufeng
    Zhao, Peng
    Wei, Ke
    Deng, Chao
    Zuo, Chijian
    Sun, Zhenhua
    ACS APPLIED MATERIALS & INTERFACES, 2025, 17 (03) : 4699 - 4710
  • [25] Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2
    Liu, Juan
    Han, Huafeng
    Yang, Binbin
    Zhang, Naifang
    Li, Jing
    Chen, Xicheng
    Wu, Jie
    Zhao, Yingying
    Yang, Yongsheng
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [26] Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test
    Wang, Qiao
    Feng, Lili
    Zhang, Haohai
    Gao, Juehua
    Mao, Changchuin
    Landesman-Bollag, Esther
    Mostoslavsky, Gustavo
    Lunderberg, Justin M.
    Zheng, Weina
    Hao, Shushun
    Gao, Wenda
    ANTIBODY THERAPEUTICS, 2022, 5 (01) : 55 - 62
  • [27] Neutralizing antibodies and cellular immune response after two doses of inactivated SARS-CoV-2 vaccine in China
    Yan, Li-Na
    Zhao, Zhong-Xin
    Wang, Zhen-Dong
    Xiao, Xiao
    Liu, Pan-Pan
    Zhang, Wen-Kang
    Gu, Xiao-Lan
    Li, Bang
    Yu, Li-Ping
    Yu, Xue-Jie
    EXPERT REVIEW OF VACCINES, 2022, 21 (10) : 1465 - 1473
  • [28] Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines
    Kyaw, Moe H. H.
    Spinardi, Julia
    Zhang, Ling
    Oh, Helen May Lin
    Srivastava, Amit
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [29] Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates
    Yao, Yan-Feng
    Wang, Ze-Jun
    Jiang, Ren-Di
    Hu, Xue
    Zhang, Hua-Jun
    Zhou, Yi-Wu
    Gao, Ge
    Chen, Ying
    Peng, Yun
    Liu, Mei-Qin
    Zhang, Ya-Nan
    Min, Juan
    Lu, Jia
    Gao, Xiao-Xiao
    Guo, Jing
    Peng, Cheng
    Shen, Xu-Rui
    Li, Qian
    Zhao, Kai
    Yang, Lian
    Wan, Xin
    Zhang, Bo
    Wang, Wen-Hui
    Wu, Jia
    Zhou, Peng
    Yang, Xing-Lou
    Shen, Shuo
    Shan, Chao
    Yuan, Zhi-Ming
    Shi, Zheng-Li
    VIROLOGICA SINICA, 2021, 36 (05) : 879 - 889
  • [30] Advances of Reverse Vaccinology for mRNA Vaccine Design against SARS-CoV-2: A Review of Methods and Tools
    da Silva, Maria Karolaynne
    de Oliveira Campos, Daniel Melo
    Akash, Shopnil
    Akter, Shahina
    Yee, Leow Chiuan
    Fulco, Umberto Laino
    Nobre Oliveira, Jonas Ivan
    VIRUSES-BASEL, 2023, 15 (10):